Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384202 | 0.92 | LMNA (0.35) | LMNAMEN1KMT2A | |
| SCHEMBL7592942 | 0.89 | — | — | |
| SCHEMBL5790760 | 0.88 | MEN1 (0.32) | LMNAMEN1KMT2ATDP1CA1 | |
| SCHEMBL5688482 | 0.86 | — | — | |
| SCHEMBL2831806 | 0.84 | — | — | |
| SCHEMBL441432 | 0.84 | — | — | |
| SCHEMBL10537932 | 0.82 | — | — | |
| SCHEMBL29281483 | 0.82 | TSHR (0.36) | LMNAMEN1KMT2APOLB | |
| SCHEMBL466023 | 0.81 | — | — | |
| SCHEMBL483349 | 0.80 | TDP1 (0.31) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | claimed |
| US-8795787-B2 | Surface modification | GREINER BIO-ONE GMBH (DE) | 2014-08-05 | — | — | US | claimed |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-05-15 | — | — | US | claimed |
| EP-2655348-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK Pharmaceuticals d.d. (SI) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085133-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-06-28 | — | — | WO | claimed |
| EP-2468736-A1 | Synthesis of intermediates for preparing anacetrapib and derivates thereof | LEK Pharmaceuticals d.d. (SI) | 2012-06-27 | — | — | EP | claimed |
| EP-2252410-B1 | SURFACE MODIFICATION | GREINER BIO ONE GMBH (DE) | 2011-12-14 | — | — | EP | claimed |
| US-20100234240-A1 | SURFACE MODIFICATION | GREINER BIO - ONE GMBH (DE) | 2010-09-16 | — | — | US | claimed |
| US-6887824-B1 | Divalent lanthanide reduction catalysts | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-05-03 | — | — | US | claimed |
| EP-1242468-A1 | DIVALENT LANTHANIDE REDUCTION CATALYSTS | The Regents of the University of California (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001021667-A1 | DIVALENT LANTHANIDE REDUCTION CATALYSTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | claimed |
| EP-0287956-B1 | Process for the preparation of 5-formylevalerianic acid esters or the corresponding acetals | BASF AG (DE) | 1993-11-24 | — | — | EP | claimed |
| JP-2188544-A | — | — | None | — | — | JP | disclosed |
| JP-3099034-A | — | — | None | — | — | JP | disclosed |
| US-12529975-B2 | Toner, developer, toner storage unit, image forming apparatus, and image forming method | RICOH COMPANY, LTD. (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250316700-A1 | ANODE COMPOSITION FOR LITHIUM-ION BATTERIES | APB CORPORATION (JP) | 2025-10-09 | — | — | US | disclosed |
| US-4346027-A | UNSATURATED OXYGEN POLYMER AND A POLYOL | MONSANTO COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-4150237-A | INTERMEDIATES IN THE FORMATION OF EPOXIDES | THE DOW CHEMICAL COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4126746-A | Halohydrin thioethers and method of preparation | THE DOW CHEMICAL COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4071563-A | Manufacture of pent-4-en-1-al | BASF AKTIENGESELLSCHAFT (DT) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | CYP2B6, CYP4B1, CIAPIN1 | LMNA 1641/4885MEN1 2799/4885KMT2A 2084/4885 |
| US-12529975-B2 | Toner, developer, toner storage unit, image forming apparatus, and image forming method | ZFR, ZMYND8, SUN2 | LMNA 4089/4885MEN1 4677/4885KMT2A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.